Literature DB >> 1879922

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

J H Eldridge1, J K Staas, J A Meulbroek, T R Tice, R M Gilley.   

Abstract

Microspheres composed of biocompatible, biodegradable poly(DL-lactide-co-glycolide) (DL-PLG) and staphylococcal enterotoxin B (SEB) toxoid were evaluated as a vaccine delivery system when subcutaneously injected into mice. As measured by circulating immunoglobulin G (IgG) antitoxin titers, the delivery of SEB toxoid via DL-PLG microspheres, 1 to 10 microns in diameter, induced an immune response which was approximately 500 times that seen with nonencapsulated toxoid. The kinetics, magnitude, and duration of the antitoxin response induced with microencapsulated toxoid were similar to those obtained when an equal toxoid dose was administered as an emulsion with complete Freund adjuvant. However, the microspheres did not induce the inflammation and granulomata formation seen with complete Freund adjuvant. The adjuvant activity of the microspheres was not dependent on the superantigenicity of SEB toxin and was equally effective at potentiating circulating IgG antitrinitrophenyl levels in response to microencapsulated trinitrophenyl-keyhole limpet hemocyanin. Empty DL-PLG microspheres were not mitogenic, and SEB toxoid injected as a mixture with empty DL-PLG microspheres was no more effective as an immunogen than toxoid alone. Antigen-containing microspheres 1 to 10 microns in diameter exhibited stronger adjuvant activity than those greater than 10 microns, which correlated with the delivery of the 1- to 10-microns, but not the greater than 10-microns, microspheres into the draining lymph nodes within macrophages. The antibody response induced through immunization with microencapsulated SEB toxoid was protective against the weight loss and splenic V beta 8+ T-cell expansion induced by intravenous toxin administration. These results show that DL-PLG microsphere vaccine delivery systems, which are composed of pharmaceutically acceptable components, possess a strong adjuvant activity for their encapsulated antigens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879922      PMCID: PMC258122          DOI: 10.1128/iai.59.9.2978-2986.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

Review 1.  T-cell responses to Mls and to bacterial proteins that mimic its behavior.

Authors:  C A Janeway; J Yagi; P J Conrad; M E Katz; B Jones; S Vroegop; S Buxser
Journal:  Immunol Rev       Date:  1989-02       Impact factor: 12.988

2.  Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response.

Authors:  J H Eldridge; J A Meulbroek; J K Staas; T R Tice; R M Gilley
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

3.  Tissue response to biodegradable injectable microcapsules.

Authors:  G E Visscher; M A Robison; G J Argentieri
Journal:  J Biomater Appl       Date:  1987-07       Impact factor: 2.646

4.  Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Authors:  O Leo; M Foo; D H Sachs; L E Samelson; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

5.  Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma.

Authors:  H Parmar; R H Phillips; S L Lightman; L Edwards; L Allen; A V Schally
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

6.  Immunogenicity of trinitrophenyl-hemocyanin: production of primary and secondary anti-hapten precipitins.

Authors:  M B Rittenberg; A A Amkraut
Journal:  J Immunol       Date:  1966-09       Impact factor: 5.422

7.  Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor.

Authors:  U D Staerz; H G Rammensee; J D Benedetto; M J Bevan
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

8.  Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response.

Authors:  G J Zigterman; H Snippe; M Jansze; J M Willers
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

9.  The T cell receptor V beta 6 domain imparts reactivity to the Mls-1a antigen.

Authors:  O Kanagawa; E Palmer; J Bill
Journal:  Cell Immunol       Date:  1989-04-01       Impact factor: 4.868

10.  The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice.

Authors:  J White; A Herman; A M Pullen; R Kubo; J W Kappler; P Marrack
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

View more
  57 in total

1.  Cross-linked protein crystals for vaccine delivery.

Authors:  N St Clair; B Shenoy; L D Jacob; A L Margolin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.

Authors:  D C Quenelle; G A Winchester; J K Staas; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.

Authors:  D C Quenelle; J K Staas; G A Winchester; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes.

Authors:  Akhilesh Kumar Shakya; Ashok Kumar; Dorota Klaczkowska; Malin Hultqvist; Kristin Hagenow; Rikard Holmdahl; Kutty Selva Nandakumar
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

Review 5.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 6.  Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.

Authors:  José M Morachis; Enas A Mahmoud; Adah Almutairi
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

Review 7.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 8.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

9.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

10.  Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Authors:  Kimberly J Hassett; Megan C Cousins; Lilia A Rabia; Chrystal M Chadwick; Joanne M O'Hara; Pradyot Nandi; Robert N Brey; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2013-04-10       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.